Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial.
暂无分享,去创建一个
A. Skene | E. Braunwald | D. Morrow | C. McCabe | B. Scirica | E. Karwatowska-Prokopczuk | C. Mccabe
[1] C. Antzelevitch,et al. Inhibition of late (sustained/persistent) sodium current: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function , 2004 .
[2] Andrew C. Zygmunt,et al. Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties , 2004, Circulation.
[3] Christopher P Cannon,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[4] C. Antzelevitch,et al. Antiarrhythmic Effects of Ranolazine in a Guinea Pig in Vitro Model of Long-QT Syndrome , 2004, Journal of Pharmacology and Experimental Therapeutics.
[5] J. Shryock,et al. Antagonism by Ranolazine of the Pro-Arrhythmic Effects of Increasing Late INa in Guinea Pig Ventricular Myocytes , 2004, Journal of cardiovascular pharmacology.
[6] B. Chaitman,et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. , 2004, Journal of the American College of Cardiology.
[7] J. M. Di Diego,et al. Electrophysiologic Properties and Antiarrhythmic Actions of a Novel Antianginal Agent , 2004, Journal of cardiovascular pharmacology and therapeutics.
[8] B. Chaitman,et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. , 2004, JAMA.
[9] B. Chaitman,et al. Ranolazine increases exercise performance and decreases hemoglobin A1C in angina patients with diabetes , 2003 .
[10] Donald M Bers,et al. Intracellular Na+ regulation in cardiac myocytes. , 2003, Cardiovascular research.
[11] E. Topol,et al. Long-Term Results After the Glycoprotein IIb/IIIa Inhibitor Abciximab in Unstable Angina: One-Year Survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV—Acute Coronary Syndrome) Trial , 2003, Circulation.
[12] M. Chandler,et al. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. , 2002, Journal of cardiac failure.
[13] Colleen E Clancy,et al. Defective cardiac ion channels: from mutations to clinical syndromes. , 2002, The Journal of clinical investigation.
[14] Carl J Pepine,et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients , 2002, Circulation.
[15] J. W. Schaeffer,et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction—summary article , 2002 .
[16] M. Chandler,et al. Short-Term Treatment With Ranolazine Improves Mechanical Efficiency in Dogs With Chronic Heart Failure , 2002, Circulation research.
[17] W. Stanley,et al. Partial fatty acid oxidation inhibitors: a potentially new class of drugs for heart failure , 2002, European journal of heart failure.
[18] E. Antman,et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.
[19] C. Pepine,et al. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. , 1999, The American journal of cardiology.
[20] E. Murphy,et al. Sodium regulation during ischemia versus reperfusion and its role in injury. , 1999, Circulation research.
[21] T. Nishimura,et al. Intracellular sodium accumulation during ischemia as the substrate for reperfusion injury. , 1999, Circulation research.
[22] J. Mccormack,et al. Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. , 1994, Cardiovascular research.
[23] M. Stern,et al. Ionic basis of ischaemic cardiac injury: insights from cellular studies. , 1994, Cardiovascular research.
[24] P. Gage,et al. A persistent sodium current in rat ventricular myocytes. , 1992, The Journal of physiology.
[25] R. Campbell,et al. Arrhythmogenesis and programmed stimulation techniques. , 1988, European heart journal.
[26] T R Fleming,et al. Designs for group sequential tests. , 1984, Controlled clinical trials.
[27] J. Mccormack,et al. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. , 1996, Circulation.